Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for BIOCYTOGEN-B?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2019–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Revenue moved from CN¥169.9M in FY2019 to CN¥1.38B in FY2025 (6-year CAGR +41.8%).
- Net income was negative in FY2019, FY2020, FY2021, FY2022, FY2023.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 0.35 | 0.53 | 0.72 | 0.98 | 1.38 |
| YoY | 39.8% | 50.6% | 34.3% | 36.8% | 40.6% |
| Net Income (CNY B) | -0.55 | -0.60 | -0.38 | 0.03 | 0.17 |
| YoY | — | — | — | — | 416.4% |
| Operating Cash Flow (CNY B) | -0.37 | -0.30 | -0.08 | 0.21 | 0.37 |
| ROE | -43.7% | -50.3% | -39.6% | 4.1% | 11.5% |
| Gross Margin | 69.8% | 73.4% | 70.6% | 77.7% | 75.8% |
| Net Margin | -153.9% | -112.7% | -53.4% | 3.4% | 12.6% |
| Debt-to-Assets | 45.6% | 58.9% | 67.7% | 65.3% | 41.5% |
Show all 7 fiscal years
| Fiscal Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | 0.17 | 0.25 | 0.35 | 0.53 | 0.72 | 0.98 | 1.38 |
| YoY | — | 49.3% | 39.8% | 50.6% | 34.3% | 36.8% | 40.6% |
| Net Income (CNY B) | -0.26 | -0.43 | -0.55 | -0.60 | -0.38 | 0.03 | 0.17 |
| YoY | — | — | — | — | — | — | 416.4% |
| Operating Cash Flow (CNY B) | -0.04 | -0.23 | -0.37 | -0.30 | -0.08 | 0.21 | 0.37 |
| ROE | — | — | -43.7% | -50.3% | -39.6% | 4.1% | 11.5% |
| Gross Margin | 57.2% | 65.9% | 69.8% | 73.4% | 70.6% | 77.7% | 75.8% |
| Net Margin | -155.0% | -168.8% | -153.9% | -112.7% | -53.4% | 3.4% | 12.6% |
| Debt-to-Assets | 141.3% | — | 45.6% | 58.9% | 67.7% | 65.3% | 41.5% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
-
Alert
Inventory DaysFinancial Quality
186.1 days, prior FY 6.5 days(+2769%)
FY2025 (ended 2025-12-31) · What is this?
-
Watch
Profit WarningMaterial Events
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
No dividends paid over the trailing 12 months.
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.